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Abstract Amylin has been postulated to antagonise or inhibit 
the action of insulin in peripheral rat tissues and thus contribute 
to, or be responsible for, the development of insulin resistance. 
We have recently reported that S15261 is a compound capable 
of increasing insulin sensitivity in ageing insulin resistant rats. In 
order to assess whether S15261 had any effects on amylin induced 
insulin resistance we used a model where amylin causes an im- 
pairement in glucose tolerance in an acute manner, by means of 
an intraportal infusion of the hormone in normal rats. We report 
here that S15261 can antagonise this amylin-induced impaired 
glucose tolerance. 
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1. Introduction 
Amylin, or islet amyloid polypeptide (IAPP) is the peptide 
component of amyloid deposits present in the pancreas of non- 
insulin dependent diabetics and in patients with insulinomas 
[1 3]. Amylin is present in normal pancreaticfl-cells in a variety 
of species including man, and is co-secreted with insulin, gener- 
ally in a ratio of 1:20-70 (insulin-to-amylin) [1]. Early in vitro 
experiments demonstrated that amylin could inhibit glycogen 
synthesis and insulin-stimulated glucose uptake in isolated rat 
soleus muscle strips [4,5]. Amylin was thus proposed as a 
counter-regulatory hormone to insulin, antagonising insulin's 
action in peripheral rat tissues [6]. In rat soleus muscle amylin 
raises cAMP levels and thereby effects conversion of 
phosphorylase b to phosphorylase a and of glycogen synthase 
a to glycogen synthase b thus accounting for its effect to inhibit 
glycogen synthesis and promote glycogenolysis. [7-9]. These 
effects in turn explain amylin's induction of hyperlactataemia 
and hyperglycaemia in rats [10,11]. Amylin has been shown to 
cause insulin resistance in rats in vivo, although at concentra- 
tions greater than those found physiologically or in pathologi- 
cal situations [13-17]. However, the selective amylin antagonist 
AC 187 markedly decreases the hyperlactataemia which accom- 
panies hyperglycaemia in rats, suggesting that amylin released 
in response to hyperglycaemia is hyperlactataemic [12]. In hu- 
mans amylin does not modify glucose metabolism during an i.v. 
glucose tolerance test (GTT) [18], or during a euglycaemic 
clamp [19]. In contrast, in euglycaemic clamp studies in rats, 
intravenous (i.v.) infusions of amylin can inhibit glucose uptake 
and decrease the effect of insulin to suppress hepatic glucose 
output [15,16]. These effects have been ascribed to amylin's 
effects on the liver [15] or on skeletal muscle [13]. It is clear that 
despite the relative controversy surrounding the pathophysiol- 
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ogical role of amylin in insulin resistance in humans, various 
animal models can provide a means of assessment of its activity. 
We have recently presented a new compound, S 15261, for the 
treatment of insulin resistance syndrome [20]. In chronic studies 
in ageing insulin resistant Sprague-Dawley rats S 15261 lowered 
plasma insulin, triglyceride and cholesterol levels and restored 
impaired glucose tolerance. Euglycaemic glucose clamp studies 
showed these effects to be related to an increase in peripheral 
glucose uptake without modification of hepatic glucose produc- 
tion [20]. We also demonstrated that when the compound is 
infused acutely into the portal vein at very low doses (20 70 
nmol/kg/h) it increases the glucose disappearance rate during 
an i.v. GTT. 
Since amylin is co-stored and co-secreted with insulin, and 
is thus secreted irectly into the portal vein, we undertook the 
present study to examine whether amylin could induce a state 
of insulin resistance when injected directly into this vein, in- 
stead of being injected at a peripheral site, and to assess the 
effects of S15261 under these circumstances. We report here 
that acute administration of amylin can impair glucose toler- 
ance and that this effect is antagonised by S15261. 
2. Experimental 
2.1. Materials 
Ketamine hydrochloride (Imalgene) was purchased from Rh6ne- 
Merieux (Lyon, France) and rat amylin amide was from Bachem (Basel, 
Switzerland). Other reagents and biochemicals were from Sigma. 
S15261, the L-isomer of 3-[2-[2-[4-[2-[~-fluorenyl acetyl amino ethyl]- 
benzoyloxy]ethyl amino]l-methoxy ethyl] trifluoromethylbenzene [20],
and S 15402, the L-isomer of [benzoyloxy ethyl amino] 1-methoxy ethyl] 
trifluoromethylbenzene, were synthesized in-house and are shown in 
Fig. 1. 
2.2. Animals" 
Male Sprague-Dawley rats of 3 months of age were used in these 
studies. They were maintained ata constant temperature (21°C) with 
a 12-h artificial ight cycle, and had free access to water and standard 
laboratory chow (AO3, UAR Laboratory chow, Epinay, Villemuisson, 
France). Fifteen days prior to experimentation animals were anesthet- 
ised with ketamine and a 0.2 mm (internal diameter) silastic catheter 
was implanted into the portal vein. Three days prior to the experiment 
a cardiac atheter was implanted. Finally, animals were fasted for 18 
h before the experiments. Body weight loss due to surgical procedures 
was in the region of 10-12 g in all groups. All experimental procedures 
were approved by the Comit6 d'Ethique de l'Institut de Recherche 
Servier, and were carried out in compliance with French law regulating 
animal experimentation (Decree No. 87-848 19th October 1987, and 
the Ministerial Decrees of 19 April 1988). 
2.3. Portal infusion and IVGTT 
The methods for the implantation of catheters, the portal infusion 
technique and the simultaneous IVGTT were as described previously 
[20,21]. Briefly, animals with implanted silastic atheters into the portal 
and jugular veins receive on day-0 a one-hour portal infusion (0.035 
ml/min) with saline, and three days later a one-hour portal infusion 
(0.035 ml/min) of amylin in the presence or absence of S15261. During 
the one-hour infusions an IVGTT is performed 30 min after beginning 
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the portal infusion by injection of glucose (500 mg/kg) and serial blood 
sampling for the following 30 min during which the portal infusion is 
maintained. The rate of glucose disappearance (Ko) during the IVGTT 
is the slope of the decrease calculated by means quare deviations 
[20,211. 
2.4. Metabolite and hormone determinations 
Plasma glucose was measured ina COBAS Mira S analyser (Roche 
Diagnostic Systems, Neuilly, France). Insulin was measured by ra- 
dioimmunoassay using a Phasedeph kit (Kabi Pharmacia Diagnostics, 
St. Quentin-en-Yvelines, France). 
2.5. Statistics 
Data are presented as means + S.E.M. and were analysed using a 
Student's t-test. 
3. Results 
In these experiments amylin was infused at doses of 2.6 and 
26 nmol/kg/h which we chose on the basis of reported ata [15]. 
Amylin infused at a rate of 2.6 nmol/kg/h was without effect 
on basal plasma glucose (not shown) or insulin levels (see the 
first 30 min period in Fig. 2). There were also no differences in 
peak glucose or insulin levels following the i.v. glucose load. In 
contrast the K~ values (Table 1) were decreased by amylin by 
67% at the higher dose, but there was no effect at the lower 
dose. Thus, amylin impaired glucose tolerance in normal rats. 
The insulin response to glucose seemed modified by the infu- 
sion of amylin at 26 nmol/kg/h (Fig. 2), but no effect was seen 
at the lower dose (not shown). Thus, whilst basal or peak 
insulin levels were not altered by amylin, the return to basal 
values was much slower. Insulin levels in NaCI controls had 
returned to basal by T60-T70, whereas in the amylin group, 
insulin levels were still much higher (by 40-50%) at these times 
and had not returned to basal even at T~2o. Therefore, the 
impaired glucose tolerance produced by amylin and shown in 
Table 1, took place despite a seemingly compensatory increase 
in insulin secretion, thereby, demonstrating the extent o which 
amylin had caused a transient insulin resistant state. 
Infusion of S15261 at a dose shown to reverse impaired 
glucose tolerance in ageing insulin resistant rats (70 nmol/kg/h, 
[20]) together with amylin (at the higher dose) normalised K~ 
values (Table 1) but did nothing to the changes in insulin secre- 
tion produced by amylin (Fig. 2). S15261 by itself was also 
without effect on insulin secretion. In contrast administration 
of S15402 had no effect on the K G values (Table 1) or on the 
insulin secretory profile (not shown). 
Table 1 
Effects of an intraportal infusion of amylin, in the presence orabsence 
of S 15261 and S 15402 on glucose disappearance rates during an IVGTT 
Amylin NaCI S 15261 S 15402 
(nmol/kg/h) (70 nmol/kg/h) (70 nmol/kg/h) 
None 3.54 + 0.24 3.45 + 0.50 3.30 + 0.45 
2.6 3.42 + 0.40 
26 1.71 + 0.27 ÷÷ 3.80 + 0.38** 2.27 + 0.13 
Glucose disappearance rates are given as the K~ values (x 10 -2) 
+ S.E.M. for 68 animals. Statistical significance is given by ++P < 0.01 
for the effects of amylin and by **P < 0.01 for the effects of the drug 
versus the saline group. 
( 




Fig. 1. Structures of S15261 and S15402. The asterisks indicate an 
asymetric carbon. 
4. Discussion 
The intraportal infusion technique coupled to an IVGTT can 
be used to assess the acute effects of a compound on glucose 
tolerance. Whilst it is not as fully informative as a euglycaemic 
clamp, it is quicker to perform and provides an indication of 
a drug's effects on glucose metabolism. We have previously 
presented such studies with two types of drugs, benfluorex [21] 
and S15261 [20]. The data presented here demonstrate hat an 
intraportal infusion of amylin can cause a transient state of 
insulin resistance innormal animals, and thus confirm previous 
observations using different methodology [13-16]. We have 
thus used the portal infusion method as a model of testing the 
effects of an insulin sensitising agent in an acute manner instead 
of in chronic studies. 
The most important observation presented here is that 
S15261 antagonised the effects of amylin to impair glucose 
tolerance. The dose of S15261 chosen for this study is that 
shown to restore normal glucose tolerance in ageing insulin 
resistant Sprague-Dawley rats [20]. In previous euglycaemic 
clamp studies we showed the compound acts to increase periph- 
eral glucose uptake, without effects on hepatic glucose output 
[21]. The data presented here support his notion as S15261 
normalised K~ values despite having no effect on amylin's ef- 
fects on the insulin secretory response to glucose (Fig. 2). More- 
over, S15261 had no effects on insulin secretion at basal evel 
either. These observations suggests that the effects of the drug 
are primarily at peripheral sites, probably at the level of skeletal 
muscle. 
One could further suggest that, in the light of the antagonism 
of its effects by S15261, the action of amylin might also be at 
the level of skeletal muscle. Controversy exists over the effects 
of amylin on hepatic glucose metabolism. Thus, whilst Koop- 
mans et al. [15] proposed that liver was the predominant organ 
of regulation by amylin, Frontoni and co-workers [13] sug- 
gested that muscle accounted for all of amylin's effects to 
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Fig. 2. Effects of an intraportal infusion of amylin in the absence or 
presence of S15261. Amylin was infused at 26 nmol/kg/h, and S15261 
at 70 nmol/kg/h. The arrow indicates the time of injection of an i.v. 
glucose load, as per section 2. Error bars have been ommitted for 
clarity, but in no case were they greater than 11%. Basal insulin levels 
were 6 + 1/IU/ml for NaCI controls, 7+ 1HU/ml for the Amylin group, 
5 + 1 ,uU/ml for the S15261 group and 7 + 1 /IU/ml for the Am- 
ylin + S15261 group. The corresponding Ti20 values were 6 + 1, 8 + 1, 
5 + 1, and 10 _+ 1/~U/ml. 
induce insulin resistance in vivo. In vitro experiments using rat 
hepatocytes have shown either an absence of effects by amylin 
on insulin-stimulated glucokinase gene expression [22] or a 
direct effect of amylin to stimulate glycogenolysis and glu- 
coneogenesis [23]. Furthermore, despite the presence of amylin 
receptors in liver membranes and in a population of hepatic 
cells [24-26], Stephens et al. [26] failed to demonstrate a direct 
effect of amylin on hepatic glucose metabolism. Finally, 
Nishimura and co-workers reported a lack of effect of amylin 
on hepatic glucose output in a perfused liver preparation [27]. 
Amylin has been reported to decrease the insulin secretory 
response to hyperglycaemia possibly by a paracrine ffect [28]. 
In the present studies amylin did not inhibit glucose-induced 
insulin secretion, but on the contrary appeared to stimulate it 
at the higher dose used. It is possible that a portal infusion of 
amylin produces a pancreatic response more similar to that 
seen in perfused pancreas preparations where amylin causes 
either no effect [29] or a stimulation [30] of insulin secretion. 
We cannot at present propose a mechanism of action for the 
effects of S15261 on amylin-induced impaired glucose toler- 
ance. The data obtained with S 15402, a compound of the same 
series as S15261 but with a reduced activity in animal models 
of insulin resistance (unpublished observations), supports the 
idea of a specific effect of S15261. In the light of its profile of 
activity we would argue that the effects of the drug are primar- 
ily at the level of glucose metabolism in skeletal muscle. Since 
amylin's effects on glucose metabolism also involve direct ef- 
fects on skeletal muscle it may be tempting to speculate as to 
whether the activity of the drug may, in part, be related to an 
antagonism of the effects of amylin in this tissue. Experiments 
in isolated rat soleus muscle are underway to attempt to answer 
this question. 
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